Cargando…

Cytokine and Chemokine Secretome and Risk of CMV Infection Following Discontinuation of Valganciclovir Prophylaxis

Detalles Bibliográficos
Autores principales:	Fernández-Ruiz, Mario, Parra, Patricia, Ruiz-Merlo, Tamara, Redondo, Natalia, Rodríguez-Goncer, Isabel, Andrés, Amado, Aguado, José María
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Health Archive
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908579/ https://www.ncbi.nlm.nih.gov/pubmed/36776902 http://dx.doi.org/10.3389/ti.2023.10979

Ejemplares similares

Cytomegalovirus Exposure and the Risk of Overall Infection After Kidney Transplantation: A Cohort Study on the Indirect Effects Attributable to Viral Replication
por: Rodríguez-Goncer, Isabel, et al.
Publicado: (2022)

Influence of single-nucleotide polymorphisms in TLR3 (rs3775291) and TLR9 (rs352139) on the risk of CMV infection in kidney transplant recipients
por: Redondo, Natalia, et al.
Publicado: (2022)

Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients
por: Johansson, Inger, et al.
Publicado: (2013)

576. Half-dose Valganciclovir Prophylaxis is Safe and Cost-effective in CMV Seropositive Renal Transplant Recipients
por: shi, yiyun, et al.
Publicado: (2020)

2646. Incidence of Myelosuppression Related to Valganciclovir Prophylaxis in Solid-Organ Transplant Recipients at High Risk of CMV Disease
por: Belga, Sara, et al.
Publicado: (2019)

Role of Valganciclovir in Children with Congenital CMV Infection: A Review of the Literature
por: Pata, Davide, et al.
Publicado: (2023)

Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients
por: Kim, Jong Man, et al.
Publicado: (2015)

1571. Cost-Effectiveness Analysis of Duration of Valganciclovir Prophylaxis Among CMV Serology Mismatched (Donor+/Recipient−) Lung Transplant Recipients
por: Tomko, Heather, et al.
Publicado: (2018)

Genetic polymorphisms in TLR3, IL10 and CD209 influence the risk of BK polyomavirus infection after kidney transplantation
por: Redondo, Natalia, et al.
Publicado: (2022)

Impact of polymorphisms in genes orchestrating innate immune responses on replication kinetics of Torque teno virus after kidney transplantation
por: Redondo, Natalia, et al.
Publicado: (2022)

1380. Real-world Effectiveness and Complications of Valganciclovir (VGC) Prophylaxis for Kidney Transplant (KT) Recipients at High Risk for Cytomegalovirus (CMV) infection (CMV Donor (D)+/Recipient (R)-)
por: Roumpz, Caroline G, et al.
Publicado: (2021)

Human Astrocytes: Secretome Profiles of Cytokines and Chemokines
por: Choi, Sung S., et al.
Publicado: (2014)

New Treatment Options for Refractory/Resistant CMV Infection
por: Walti, Carla Simone, et al.
Publicado: (2023)

2715. Toxicities and clinical consequences of valganciclovir prophylaxis in solid organ transplant recipients
por: Lahoud, Chloe, et al.
Publicado: (2023)

Role of cytomegalovirus infection after kidney transplantation on the subsequent risk of atherosclerotic and thrombotic events()
por: Rodríguez-Goncer, Isabel, et al.
Publicado: (2022)

Efficacy of low-dose valganciclovir in CMV R+ lung transplant recipients: a retrospective comparative analysis
por: Hunt, Jessica, et al.
Publicado: (2021)

Rat astrocytes during anoxia: Secretome profile of cytokines and chemokines
por: Samy, Zeinab Adel, et al.
Publicado: (2018)

Effects of oral valganciclovir prophylaxis for cytomegalovirus infection in heart transplant patients
por: Doesch, Andreas O, et al.
Publicado: (2012)

High frequency of valganciclovir underdosing for cytomegalovirus prophylaxis after renal transplantation
por: Rissling, Olesja, et al.
Publicado: (2018)

CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients
por: Chavaz, Lara, et al.
Publicado: (2023)

Efficacy of Extended Valganciclovir Prophylaxis in Preventing Cytomegalovirus Infection in Pediatric Kidney Transplantation
por: Hashim, Faris, et al.
Publicado: (2014)

The Association Between Cytomegalovirus Infection and Cardiac Allograft Vasculopathy in the Era of Antiviral Valganciclovir Prophylaxis
por: Klimczak-Tomaniak, Dominika, et al.
Publicado: (2019)

Valganciclovir: Leucopenia: case report
Publicado: (2021)

Use of letermovir‐valganciclovir combination as a step‐down treatment after foscarnet for ganciclovir‐resistant CMV infection in kidney transplant recipients
por: Rho, Elena, et al.
Publicado: (2021)

The pharmacokinetics of valganciclovir prophylaxis in pediatric solid organ transplant patients at risk for Epstein–Barr virus disease
por: Vezina, Heather E, et al.
Publicado: (2009)

1702. Assessing the Safety and Efficacy of Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Solid Organ Transplant Recipients on Hemodialysis
por: Yee, Jason, et al.
Publicado: (2020)

1747. Impact of Inappropriately Low Cytomegalovirus (CMV) Prophylaxis Dosing on CMV Outcomes Among Lung Transplant (LT) Recipients
por: Watts, Corey, et al.
Publicado: (2019)

Comparison of Three Renal Function Formulas for Ganciclovir/Valganciclovir Dose Individualization in CMV-Infected Solid Organ Transplantation Patients Using a Population Approach
por: Lalagkas, Panagiotis Nikolaos, et al.
Publicado: (2023)

Detection of Ganciclovir-Resistant Cytomegalovirus in a Prospective Cohort of Kidney Transplant Recipients Receiving Subtherapeutic Valganciclovir Prophylaxis
por: Wong, Diana D., et al.
Publicado: (2022)

Cytomegalovirus retinitis treated with valganciclovir in Wegener’s granulomatosis
por: Kabata, Yoshiaki, et al.
Publicado: (2012)

Valganciclovir as Add-On to Standard Therapy in Secondary Glioblastoma
por: Stragliotto, Giuseppe, et al.
Publicado: (2020)

Mycophenolate-mofetil/valganciclovir: Neutropenia: case report
Publicado: (2022)

1703. Hematologic Toxicity of Valganciclovir Prophylaxis in Solid Organ Transplant Recipients as a Function of Weight-adjusted Ganciclovir Exposure
por: Campanella, Toni A, et al.
Publicado: (2020)

Cytomegalovirus prophylaxis using low-dose valganciclovir in patients with acute leukemia undergoing allogeneic hematopoietic stem-cell transplantation
por: Li, Po-Hsien, et al.
Publicado: (2021)

Safety of Valganciclovir 450 mg 3 Times Weekly for Cytomegalovirus Prophylaxis in Solid Organ Transplant Recipients Requiring Hemodialysis
por: Ecabert, Danielle, et al.
Publicado: (2021)

Cytomegalovirus Hyper Immunoglobulin for CMV Prophylaxis in Thoracic Transplantation
por: Rea, Federico, et al.
Publicado: (2016)

Cytokine and Reward Circuitry Relationships in Treatment-Resistant Depression
por: Rengasamy, Manivel, et al.
Publicado: (2021)

Economic Impact of European Liver and Intestine Transplantation Association (ELITA) Recommendations for Hepatitis B Prophylaxis After Liver Transplantation
por: Cortesi, Paolo Angelo, et al.
Publicado: (2023)

First Experience With Extracorporeal Cytokine Adsorption Therapy After Lung Transplantation
por: Peyneau, Marine, et al.
Publicado: (2022)

Cytokines Removal During Ex-Vivo Lung Perfusion: Initial Clinical Experience
por: Boffini, Massimo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8151jkph1bktl4rmg5o8ldo29l